Compound Nanoparticle 5HMF-Prodrug Formulations for Optimized Anti-Sickling Therapy
Stephen C. Rogers(Washington University in St. Louis), Allan Doctor(Washington University in St. Louis), Martin K. Safo(Virginia Commonwealth University), Nancy Anabaraonye(Children's Hospital of Philadelphia), Maria R. Baer(University of Maryland, Baltimore), Dipanjan Pan(Pennsylvania State University), Parikshit Moitra(Indian Institute of Science Education and Research Berhampur), Osheiza Abdulmalik(Children's Hospital of Philadelphia), Nicole Glynn-Cunningham(University of Maryland, Baltimore), Zohreh Safari(University of Maryland, Baltimore), Joy Okhuevbie(University of Maryland, Baltimore), Qihong Wang(Johns Hopkins University), Jennie Y. Law(University of Maryland, Baltimore), Mary Brummet(University of Maryland, Baltimore)
Cited by 0
Related Papers
Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i> -Mutated AML
|New England Journal of Medicine|2019|1.3k
KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study
|The Lancet|2021|795
<i>IDH1</i> and <i>IDH2</i> Gene Mutations Identify Novel Molecular Subsets Within De Novo Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study
|Journal of Clinical Oncology|2010|764